Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, Rizvi NA, Hirsch FR, Selvaggi G, Szustakowski JD, Sasson A, Golhar R, Vitazka P, Chang H, Geese WJ, Antonia SJ.

Cancer Cell. 2019 Feb 11;35(2):329. doi: 10.1016/j.ccell.2019.01.011. No abstract available.

PMID:
30753829
2.

Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade.

Boland JL, Zhou Q, Martin M, Callahan MK, Konner J, O'Cearbhaill RE, Friedman CF, Tew W, Makker V, Grisham RN, Hensley ML, Zecca N, Iasonos AE, Snyder A, Hyman DM, Sabbatini P, Aghajanian C, Cadoo KA, Zamarin D.

Gynecol Oncol. 2019 Feb;152(2):251-258. doi: 10.1016/j.ygyno.2018.11.025. Epub 2018 Nov 22.

3.

The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management.

Girotra M, Hansen A, Farooki A, Byun DJ, Min L, Creelan BC, Callahan MK, Atkins MB, Sharon E, Antonia SJ, West P, Gravell AE; Investigational Drug Steering Committee (IDSC) Immunotherapy Task Force collaboration.

JNCI Cancer Spectr. 2018 Jul;2(3):pky021. doi: 10.1093/jncics/pky021. Epub 2018 Jul 19. Review.

4.

Relationship of Fitness and Wheelchair Mobility With Encounters, Avoidances, and Perception of Environmental Barriers Among Manual Wheelchair Users With Spinal Cord Injury.

Callahan MK, Cowan RE.

Arch Phys Med Rehabil. 2018 Oct;99(10):2007-2014.e3. doi: 10.1016/j.apmr.2018.06.013. Epub 2018 Jul 5.

PMID:
29981312
5.

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, Rizvi NA, Hirsch FR, Selvaggi G, Szustakowski JD, Sasson A, Golhar R, Vitazka P, Chang H, Geese WJ, Antonia SJ.

Cancer Cell. 2018 May 14;33(5):853-861.e4. doi: 10.1016/j.ccell.2018.04.001. Epub 2018 May 3. Erratum in: Cancer Cell. 2019 Feb 11;35(2):329.

PMID:
29731394
6.

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.

Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, Ni A, Novik JB, Mangarin LMB, Abu-Akeel M, Liu C, Sauter JL, Rekhtman N, Chang E, Callahan MK, Chaft JE, Voss MH, Tenet M, Li XM, Covello K, Renninger A, Vitazka P, Geese WJ, Borghaei H, Rudin CM, Antonia SJ, Swanton C, Hammerbacher J, Merghoub T, McGranahan N, Snyder A, Wolchok JD.

Cancer Cell. 2018 May 14;33(5):843-852.e4. doi: 10.1016/j.ccell.2018.03.018. Epub 2018 Apr 12.

7.

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.

Teo MY, Seier K, Ostrovnaya I, Regazzi AM, Kania BE, Moran MM, Cipolla CK, Bluth MJ, Chaim J, Al-Ahmadie H, Snyder A, Carlo MI, Solit DB, Berger MF, Funt S, Wolchok JD, Iyer G, Bajorin DF, Callahan MK, Rosenberg JE.

J Clin Oncol. 2018 Jun 10;36(17):1685-1694. doi: 10.1200/JCO.2017.75.7740. Epub 2018 Feb 28.

8.

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.

Rosner S, Kwong E, Shoushtari AN, Friedman CF, Betof AS, Brady MS, Coit DG, Callahan MK, Wolchok JD, Chapman PB, Panageas KS, Postow MA.

Cancer Med. 2018 Mar;7(3):690-697. doi: 10.1002/cam4.1356. Epub 2018 Feb 22.

9.

Introduction by the Guest Editors: The PD-1 Axis in Cancer Therapy: The Irony in a Name.

Wolchok JD, Callahan MK.

Cancer J. 2018 Jan/Feb;24(1):1. doi: 10.1097/PPO.0000000000000305. No abstract available.

PMID:
29360720
10.

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.

Callahan MK, Kluger H, Postow MA, Segal NH, Lesokhin A, Atkins MB, Kirkwood JM, Krishnan S, Bhore R, Horak C, Wolchok JD, Sznol M.

J Clin Oncol. 2018 Feb 1;36(4):391-398. doi: 10.1200/JCO.2017.72.2850. Epub 2017 Oct 17.

11.

OncoKB: A Precision Oncology Knowledge Base.

Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, Rudolph JE, Yaeger R, Soumerai T, Nissan MH, Chang MT, Chandarlapaty S, Traina TA, Paik PK, Ho AL, Hantash FM, Grupe A, Baxi SS, Callahan MK, Snyder A, Chi P, Danila D, Gounder M, Harding JJ, Hellmann MD, Iyer G, Janjigian Y, Kaley T, Levine DA, Lowery M, Omuro A, Postow MA, Rathkopf D, Shoushtari AN, Shukla N, Voss M, Paraiso E, Zehir A, Berger MF, Taylor BS, Saltz LB, Riely GJ, Ladanyi M, Hyman DM, Baselga J, Sabbatini P, Solit DB, Schultz N.

JCO Precis Oncol. 2017 Jul;2017. doi: 10.1200/PO.17.00011. Epub 2017 May 16.

12.

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J.

N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11.

13.

Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.

Shoushtari AN, Friedman CF, Navid-Azarbaijani P, Postow MA, Callahan MK, Momtaz P, Panageas KS, Wolchok JD, Chapman PB.

JAMA Oncol. 2018 Jan 1;4(1):98-101. doi: 10.1001/jamaoncol.2017.2391.

14.

Health-related quality of life results from the phase III CheckMate 067 study.

Schadendorf D, Larkin J, Wolchok J, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao C, Wagstaff J, Callahan MK, Postow MA, Smylie M, Ferrucci PF, Dummer R, Hill A, Taylor F, Sabater J, Walker D, Kotapati S, Abernethy A, Long GV.

Eur J Cancer. 2017 Sep;82:80-91. doi: 10.1016/j.ejca.2017.05.031. Epub 2017 Jun 23.

15.

Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab.

Friedman CF, Clark V, Raikhel AV, Barz T, Shoushtari AN, Momtaz P, Callahan MK, Wolchok JD, Chapman PB, Hellmann MD, Postow MA.

J Natl Cancer Inst. 2016 Dec 31;109(4). doi: 10.1093/jnci/djw260. Print 2017 Apr.

16.

Corrigendum: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET.

Peinado H, Alecˇković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, García-Santos G, Ghajar CM, Nitadori-Hoshino A, Hoffman C, Badal K, Garcia BA, Callahan MK, Yuan J, Martins VR, Skog J, Kaplan RN, Brady MS, Wolchok JD, Chapman PB, Kang Y, Bromberg J, Lyden D.

Nat Med. 2016 Dec 6;22(12):1502. doi: 10.1038/nm1216-1502b. No abstract available.

PMID:
27923027
17.

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.

Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E, Pillai RN, Ott PA, de Braud F, Morse M, Le DT, Jaeger D, Chan E, Harbison C, Lin CS, Tschaika M, Azrilevich A, Rosenberg JE.

Lancet Oncol. 2016 Nov;17(11):1590-1598. doi: 10.1016/S1470-2045(16)30496-X. Epub 2016 Oct 9. Erratum in: Lancet Oncol. 2019 Feb;20(2):e71.

18.

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss MH, Rudin CM, Rizvi H, Hou X, Rodriguez K, Albano M, Gordon RA, Leduc C, Rekhtman N, Harris B, Menzies AM, Guminski AD, Carlino MS, Kong BY, Wolchok JD, Postow MA, Long GV, Hellmann MD.

J Clin Oncol. 2017 Mar;35(7):709-717. doi: 10.1200/JCO.2016.68.2005. Epub 2016 Sep 30.

19.

Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis.

Kuk D, Shoushtari AN, Barker CA, Panageas KS, Munhoz RR, Momtaz P, Ariyan CE, Brady MS, Coit DG, Bogatch K, Callahan MK, Wolchok JD, Carvajal RD, Postow MA.

Oncologist. 2016 Jul;21(7):848-54. doi: 10.1634/theoncologist.2015-0522. Epub 2016 Jun 10.

20.

Targeting T Cell Co-receptors for Cancer Therapy.

Callahan MK, Postow MA, Wolchok JD.

Immunity. 2016 May 17;44(5):1069-78. doi: 10.1016/j.immuni.2016.04.023. Review.

21.

Immune Checkpoint Therapy in Melanoma.

Callahan MK.

Cancer J. 2016 Mar-Apr;22(2):73-80. doi: 10.1097/PPO.0000000000000183. Review.

PMID:
27111901
22.

Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response.

Samstein RM, Carvajal RD, Postow MA, Callahan MK, Shoushtari AN, Patel SG, Lee NY, Barker CA.

Head Neck. 2016 Sep;38(9):1310-7. doi: 10.1002/hed.24435. Epub 2016 Apr 4.

23.

Preclinical Experimental and Mathematical Approaches for Assessing Effective Doses of Inhaled Drugs, Using Mometasone to Support Human Dose Predictions.

Caniga M, Cabal A, Mehta K, Ross DS, Gil MA, Woodhouse JD, Eckman J, Naber JR, Callahan MK, Goncalves L, Hill SE, Mcleod RL, McIntosh F, Freke MC, Visser SA, Johnson N, Salmon M, Cicmil M.

J Aerosol Med Pulm Drug Deliv. 2016 Aug;29(4):362-77. doi: 10.1089/jamp.2015.1253. Epub 2016 Feb 9.

PMID:
26859446
24.

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis.

Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, No D, Gobourne A, Littmann E, Huttenhower C, Pamer EG, Wolchok JD.

Nat Commun. 2016 Feb 2;7:10391. doi: 10.1038/ncomms10391.

25.

A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma.

Shoushtari AN, Ong LT, Schoder H, Singh-Kandah S, Abbate KT, Postow MA, Callahan MK, Wolchok J, Chapman PB, Panageas KS, Schwartz GK, Carvajal RD.

Melanoma Res. 2016 Jun;26(3):272-7. doi: 10.1097/CMR.0000000000000234.

26.

Reply to A. Indini et al.

Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D'Angelo SP, Woo KM, Panageas KS, Wolchok JD, Chapman PB.

J Clin Oncol. 2016 Mar 20;34(9):1018-9. doi: 10.1200/JCO.2015.65.7007. Epub 2016 Jan 19. No abstract available.

PMID:
26786917
27.

Checkpoint Blockade for the Treatment of Advanced Melanoma.

Callahan MK, Flaherty CR, Postow MA.

Cancer Treat Res. 2016;167:231-50. doi: 10.1007/978-3-319-22539-5_9. Review.

PMID:
26601865
28.

Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists.

Callahan MK, Wolchok JD.

Semin Oncol. 2015 Aug;42(4):573-86. doi: 10.1053/j.seminoncol.2015.05.008. Epub 2015 Jun 3. Review.

PMID:
26320062
29.

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.

Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D'Angelo SP, Woo KM, Panageas KS, Wolchok JD, Chapman PB.

J Clin Oncol. 2015 Oct 1;33(28):3193-8. doi: 10.1200/JCO.2015.60.8448. Epub 2015 Aug 17.

30.

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD.

N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.

31.

Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab.

Minor DR, Puzanov I, Callahan MK, Hug BA, Hoos A.

Pigment Cell Melanoma Res. 2015 Sep;28(5):611-2. doi: 10.1111/pcmr.12383. Epub 2015 Jun 23. No abstract available.

32.

On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation.

Lesokhin AM, Callahan MK, Postow MA, Wolchok JD.

Sci Transl Med. 2015 Mar 25;7(280):280sr1. doi: 10.1126/scitranslmed.3010274. Review.

PMID:
25810313
33.

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic.

Callahan MK, Postow MA, Wolchok JD.

Front Oncol. 2015 Jan 15;4:385. doi: 10.3389/fonc.2014.00385. eCollection 2014. Review.

34.

Immune Checkpoint Blockade in Cancer Therapy.

Postow MA, Callahan MK, Wolchok JD.

J Clin Oncol. 2015 Jun 10;33(17):1974-82. doi: 10.1200/JCO.2014.59.4358. Epub 2015 Jan 20. Review.

35.

Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody.

Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P.

Sci Transl Med. 2014 Apr 2;6(230):230ra45. doi: 10.1126/scitranslmed.3008002.

36.

Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.

Abdel-Wahab O, Klimek VM, Gaskell AA, Viale A, Cheng D, Kim E, Rampal R, Bluth M, Harding JJ, Callahan MK, Merghoub T, Berger MF, Solit DB, Rosen N, Levine RL, Chapman PB.

Cancer Discov. 2014 May;4(5):538-45. doi: 10.1158/2159-8290.CD-13-1038. Epub 2014 Mar 3.

37.

Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor.

Callahan MK, Masters G, Pratilas CA, Ariyan C, Katz J, Kitano S, Russell V, Gordon RA, Vyas S, Yuan J, Gupta A, Wigginton JM, Rosen N, Merghoub T, Jure-Kunkel M, Wolchok JD.

Cancer Immunol Res. 2014 Jan;2(1):70-9. doi: 10.1158/2326-6066.CIR-13-0160.

38.

Immune modulation in cancer with antibodies.

Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD.

Annu Rev Med. 2014;65:185-202. doi: 10.1146/annurev-med-092012-112807. Epub 2013 Oct 30. Review.

PMID:
24188664
39.

Checkpoint modulation in melanoma: an update on ipilimumab and future directions.

Page DB, Postow MA, Callahan MK, Wolchok JD.

Curr Oncol Rep. 2013 Oct;15(5):500-8. doi: 10.1007/s11912-013-0337-1. Review.

40.

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.

Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, Giobbie-Hurder A, Lawrence DP, Ibrahim N, Ott PA, Flaherty KT, Sullivan RJ, Harding JJ, D'Angelo S, Dickson M, Schwartz GK, Chapman PB, Wolchok JD, Hodi FS, Carvajal RD.

Cancer. 2013 Oct 15;119(20):3687-95. doi: 10.1002/cncr.28282. Epub 2013 Aug 2.

41.

Nivolumab plus ipilimumab in advanced melanoma.

Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M.

N Engl J Med. 2013 Jul 11;369(2):122-33. doi: 10.1056/NEJMoa1302369. Epub 2013 Jun 2.

42.

Ipilimumab for patients with advanced mucosal melanoma.

Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, Callahan MK, Harding JJ, D'Angelo SP, Dickson MA, Schwartz GK, Chapman PB, Gnjatic S, Wolchok JD, Hodi FS, Carvajal RD.

Oncologist. 2013 Jun;18(6):726-32. doi: 10.1634/theoncologist.2012-0464. Epub 2013 May 28.

43.

At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.

Callahan MK, Wolchok JD.

J Leukoc Biol. 2013 Jul;94(1):41-53. doi: 10.1189/jlb.1212631. Epub 2013 May 10. Review.

44.

Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types.

Ascierto PA, Kalos M, Schaer DA, Callahan MK, Wolchok JD.

Clin Cancer Res. 2013 Mar 1;19(5):1009-20. doi: 10.1158/1078-0432.CCR-12-2982.

45.

Immunomodulatory therapy for melanoma: ipilimumab and beyond.

Callahan MK, Postow MA, Wolchok JD.

Clin Dermatol. 2013 Mar-Apr;31(2):191-9. doi: 10.1016/j.clindermatol.2012.08.006. Review.

46.

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas.

Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, Huang A, Wong WL, Callahan MK, Merghoub T, Wolchok JD, de Stanchina E, Chandarlapaty S, Poulikakos PI, Fagin JA, Rosen N.

Cancer Cell. 2012 Nov 13;22(5):668-82. doi: 10.1016/j.ccr.2012.10.009.

47.

Progression of RAS-mutant leukemia during RAF inhibitor treatment.

Callahan MK, Rampal R, Harding JJ, Klimek VM, Chung YR, Merghoub T, Wolchok JD, Solit DB, Rosen N, Abdel-Wahab O, Levine RL, Chapman PB.

N Engl J Med. 2012 Dec 13;367(24):2316-21. doi: 10.1056/NEJMoa1208958. Epub 2012 Nov 7.

48.

Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET.

Peinado H, Alečković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, García-Santos G, Ghajar C, Nitadori-Hoshino A, Hoffman C, Badal K, Garcia BA, Callahan MK, Yuan J, Martins VR, Skog J, Kaplan RN, Brady MS, Wolchok JD, Chapman PB, Kang Y, Bromberg J, Lyden D.

Nat Med. 2012 Jun;18(6):883-91. doi: 10.1038/nm.2753. Erratum in: Nat Med. 2016 Dec 6;22(12 ):1502.

49.

The 6-min push test is reliable and predicts low fitness in spinal cord injury.

Cowan RE, Callahan MK, Nash MS.

Med Sci Sports Exerc. 2012 Oct;44(10):1993-2000. doi: 10.1249/MSS.0b013e31825cb3b6.

PMID:
22617394
50.

Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe".

Curran MA, Callahan MK, Subudhi SK, Allison JP.

Immunobiology. 2012 Jun;217(6):590-2. doi: 10.1016/j.imbio.2011.11.001. Epub 2011 Nov 17. No abstract available.

PMID:
22459268

Supplemental Content

Loading ...
Support Center